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related events. We assessed the outcomes of patients with vs without rapid response to
treatment of AIH in a large international cohort.METHODS: We performed a retrospective cohort study, collecting data from 2 independent cohorts of
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receiver operating characteristic curve and Youden index to calculate the optimal percentage
decrease in level of aspartate aminotransferase (AST) after 8 weeks of treatment that associ-
ated with normalization of transaminase levels after 26 weeks of treatment with predniso(lo)ne
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1610 Pape et al Clinical Gastroenterology and Hepatology Vol. 18, No. 7confirmed in the validation cohort. Results from measurement of alanine aminotransferase did
not differ significantly from those of AST for the primary outcome. Slow responders (without
normalization of transaminases after 1 year) had the highest risk of liver transplantation or
liver-related death.CONCLUSIONS: In a retrospective study of patients with AIH, we found that a rapid response to treatment,
based on level of AST after 8 weeks, associates with normalization of transaminase levels in the
following year. Patients with a rapid response also have a lower risk of liver-related death or
transplantation than patients without this rapid response.Keywords: Induction Therapy; Prognostic Factor; Liver Enzyme; Steroid.Autoimmune hepatitis (AIH) is a rare, chronic liverdisease that is characterized by elevated serum
transaminases and IgG, inflammatory liver histology, and
presence of circulating autoantibodies.1,2 Treatment
consists of induction therapy with corticosteroids fol-
lowed by maintenance therapy with azathioprine.3
Biochemical remission is defined as normalization of
alanine aminotransferase (ALT), aspartate aminotrans-
ferase (AST), and IgG below the upper limit of normal
(ULN). This endpoint is associated with low histologic
disease activity and regression of fibrosis.4
Reports on the relationship between elevation and
dynamics of transaminases and relevant outcomes are
limited. Cases with AST levels greater than 10 times ULN
at presentation have a lower risk of developing cirrhosis
and had a better long-term outcome.5 Patients who do
not achieve at least a 50% decrease of transaminases
within 6 months run an increased risk for liver
transplantation.6
A large proportion of patients with AIH have a rapid
decline of serum transaminases in the first weeks after
initiation of steroids, persisting throughout treatment.
The exact relationship between the rapidity of decline in
transaminases during treatment and long-term clinical
events, such as liver transplantation and liver-related
mortality, is unknown. We hypothesized that patients
with a rapid decrease in transaminases have a higher
probability to achieve biochemical remission and a lower
risk for liver-related morbidity later in time. Therefore,
we used data from 2 independent cohorts of patients with
AIH to investigate the relationship between early treat-
ment response and the effect on biochemical remission,
liver-related mortality, and liver transplantation.Methods
Study Design
We performed a retrospective cohort study, estab-
lishing 2 independent cohorts of patients with AIH from
12 centers across 7 countries in Europe. We included
patients with a probable or definite AIH diagnosis ac-
cording to the simplified International Autoimmune
Hepatitis Group score.7–9 When patients scored as “noAIH” by the simplified criteria, but were treated by their
physicians as patients with AIH, the revised score was
used to calculate a score per patient. Only patients with a
pretreatment score >10 were classified as AIH and were
included in our study. Only patients who were 18 years
old at time of diagnosis were included. We excluded
patients who had variant syndromes with primary biliary
cholangitis; primary sclerosing cholangitis; or other
forms of liver disease, such as viral hepatitis and
nonalcoholic steatohepatitis. Ethics approval was waived
after review by local institutional review board.
Data Collection
Patient data were retrieved from patient records and
local databases. We collected demographics variables,
serologic, histologic, biochemical, and treatment vari-
ables. The original pathology report was used to classify
a patient as cirrhotic. Additionally, data on mortality and
liver transplantation were collected. Laboratory values
were collected at baseline and after 8, 26, and 52 weeks
of therapy.
Outcomes
Primary outcomes were normalization of trans-
aminases after 26 and 52 weeks of treatment. The
gender-specific ULN for ALT and AST of each center was
used. Secondary endpoints included biochemical remis-
sion, defined as normalization of transaminases and
normal serum IgG after 26 and 52 weeks of treatment,
liver-related mortality or liver transplantation, all-cause
mortality, and development of hepatocellular carci-
noma. In case of missing ALT or AST values at the 26- or
52-week time point, we used last observation carried
forward to account for missing values.
Analysis
We randomly generated a discovery and validation
cohort with stratification for baseline predniso(lo)ne
dose. First, we analyzed the correlation between per-
centage decrease of AST after 8 weeks and normalization
of transaminases after 26 weeks in the discovery cohort
What You Need to Know
Background
Changes in serum levels of transaminases immedi-
ately after initiation of treatment for autoimmune
hepatitis (AIH) might be associated with biochemical
markers of remission and liver-related events.
Findings
In a retrospective study of patients with AIH, we
found that a rapid response to treatment, based on
level of aspartate aminotransferase after 8 weeks,
associates with normalization of transaminase levels
at 26 and 52 weeks. Patients with a rapid response
also have a lower risk of liver-related death or
transplantation than patients without this rapid
response. Patients with a slow response and without
normalization of transaminases after one year had
the highest chance of liver transplantation or liver
related death.
Implications for patient care
Levels of aminotransferases to should monitored
immediate after patients with AIH begin treatment
with steroids, to identify those likely to respond.
June 2020 Rapid Treatment Response in AIH 1611(n ¼ 370) using a receiver operating characteristic curve
analysis. The Youden index was calculated to generate a
cutoff level of percentage of AST decrease after 8 weeks.
Second, patients from the discovery cohort were
divided into 2 groups based on the cutoff, generated
from the first analysis. Patients with a percentage fall of
AST after 8 weeks above the cutoff were classified as
“rapid responders” and were compared with patients
with a fall of AST below the cutoff. Univariate compari-
sons between the 2 groups were made with the chi-
square test, Mann-Whitney U test, or Student t test as
appropriate. We applied logistic regression to determine
endpoints in the 2 groups of patients. The final regres-
sion model included institute, cirrhosis, acute-severe AIH
(AS-AIH defined as a presentation with an international
normalized ratio 1.5 without evidence of cirrhosis10),
predniso(lo)ne dose, use of maintenance therapy, AST at
baseline, and bilirubin at baseline. Results of the multi-
variable logistic regression are presented as odds ratio
(OR) and 95% confidence interval (CI). We used Kaplan-
Meier curves with log-rank testing and Cox regression
with adjustment for confounders for the composite
endpoint of liver-related mortality and transplantation.
Results of the Cox regression analysis are presented as
hazard ratio (HR) with 95% CI.
Third, the cutoff generated from the discovery cohort
was used to determine outcomes in the validation cohort
(n ¼ 370). We performed similar univariate and multi-
variable analyses as in the discovery cohort. Fourth, we
performed a subgroup analysis in both cohorts combined
on patients with cirrhosis at presentation. Additionally,
we performed exploratory analyses targeting slow re-
sponders who achieved normalization of transaminases
at Week 52. Analysis for the primary and secondary
outcomes was also performed with percentage ALT
decrease as the independent variable in both cohorts. P
< .05 was considered statistically significant. Statistical




Both the discovery and validation cohort consisted of
370 patients. Most patients were female (74.5%). Pa-
tients in the validation cohort were slightly older at time
of diagnosis compared with patients in the discovery
cohort (49.58 years vs 47.09 years; P ¼ .04). Other
baseline and treatment characteristics were comparable
between the cohorts (Supplementary Table 1).
Receiver Operating Characteristic Analysis
Percentage decrease of AST after 8 weeks of treat-
ment was significantly associated with normalization of
transaminases at 26 weeks of treatment in receiveroperating characteristic analysis (area under the curve,
0.65; 95% CI, 0.59–0.71; P < .001). The highest Youden
index was 0.274, which corresponded with an AST
decrease of 80%. This percentage was used as cutoff to
determine patients with a rapid treatment response.
Corresponding sensitivity, specificity, and positive
predictive value were 64.6%, 62.8%, and 77.3%,
respectively.Discovery Cohort: Baseline Characteristics
Of all patients in the discovery cohort, 60.8% (225/
370) of patients were scored as rapid treatment re-
sponders (80% AST decrease after 8 weeks). Rapid
responders had significantly higher transaminases
(ALT  ULN 21.34 vs 3.27; P < .001; AST  ULN 19.29 vs
2.61; P< .001) and total bilirubin (107 vs 21 mmol/L; P<
.001) levels at baseline when compared with patients
without a rapid treatment response (Table 1). Rapid re-
sponders were less likely to have cirrhosis at baseline
when compared with slow responders (13.8% vs 24.1%;
P ¼ .01) and were more likely to have AS-AIH (21.8% vs
6.9%; P< .001). Patients with a rapid treatment response
were treated with higher initial predniso(lo)ne dosages
(0.73 mg/kg/day vs 0.50 mg/kg/day; P < .001).Discovery Cohort: Outcomes
Rapid responders had higher rates of normalization
of transaminases at 26 weeks compared with patients
Table 1. Baseline and Treatment Characteristics of the Discovery Cohort
<80% AST decrease at
week 8 (n ¼ 145)
80% AST decrease at
week 8 (n ¼ 225) P value
Female sex, n (%) 105 (72.4) 171 (76) .44
Age at diagnosis, y (SD) 48.08 (16.39) 46.46 (16.07) .35
Probable AIH diagnosis, n (%) 66 (45.5) 100 (44.4) .84
Definite AIH diagnosis, n (%) 79 (54.4) 125 (55.6) .84
ALT  ULN, median (IQR) 3.27 (5.59) 21.34 (28.31) < .001
AST  ULN, median (IQR) 2.61 (4.16) 19.29 (22.70) < .001
Bilirubin (mmol/L), median (IQR) 21 (37.5) 107 (207.1) < .001
INR, median (IQR)a 1.10 (0.29) 1.25 (0.54) < .001
IgG (g/L), median (IQR) 17.73 (13.2) 20.0 (11.7) .07
Cirrhosis, n (%) 35 (24.1) 31 (13.8) .01
AS-AIH, n (%) 10 (6.9) 49 (21.8) < .001
Treatment characteristics
Prednisone dose at start (mg/kg), median (IQR) 0.50 (0.44) 0.73 (0.81) < .001
Predniso(lo)ne dose at start (mg/d), median (IQR) 40 (40) 50 (68) < .001
On predniso(lo)ne at 26 wk, n (%) 96 (96.0) 149 (94.3) .54
Predniso(lo)ne dose at 26 wk (mg/d), median (IQR) 7.5 (10.0) 7.5 (5.0) .04
On predniso(lo)ne at 52 wk, n (%) 62 (82.7) 113 (82.5) .97
Predniso(lo)ne dose at 52 wk (mg/d), median (IQR) 5.0 (7.5) 5.0 (5.0) .46
Use of maintenance therapy at wk 26, n (%) 105 (72.4) 173 (76.9) .33
AZA 86 (59.3) 148 (65.8) .21
MMF 4 (2.8) 6 (2.7) .96
TAC 1 (0.7) 2 (0.9) .84
6-MP 7 (4.8) 8 (3.6) .55
6-TG 0 1 (0.4) .42
CsA 3 (2.1) 4 (1.8) .84
Other 1 (0.7) 3 (1.3) .56
NOTE. Patients are divided into 2 groups based on their treatment response.
6-MP, 6-mercaptopurine; 6-TG, 6-tioguanine; AIH, autoimmune hepatitis; ALT, alanine aminotransferase; AS-AIH, acute-severe autoimmune hepatitis; AST,
aspartate aminotransferase; AZA, azathioprine; CsA, cyclosporine; IAIHG, International Autoimmune Hepatitis Group; INR, international normalized ratio; IQR,
interquartile range; MMF, mycophenolate mofetil; SD, standard deviation; TAC, tacrolimus; ULN, upper limit of normal.
aAvailable for 291 patients.
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.001). This difference persisted after 52 weeks of treat-
ment: 86.7% of rapid responders had normalization of
transaminases versus 64.8% of nonrapid responders (P
< .001). In a subgroup of patients with available IgG (n ¼
227 for 26 weeks, n ¼ 210 for 52 weeks), we found that
biochemical remission rates were higher in the rapid
responders when compared with nonrapid responders:
77.1% versus 52.9% (P < .001) and 79.7% versus 61.2%
(P ¼ .004) or 26 and 52 weeks, respectively (Table 2).
Multivariable logistic regression showed that rapid
responders had a higher probability to reach normali-
zation of transaminases after 26 weeks (OR, 3.63; 95%
CI, 1.94–6.79; P < .001) and 52 weeks (OR, 4.99; 95% CI,
2.44–10.24; P <.001) of treatment. The same results
were observed for biochemical remission in patients
with available IgG: ORs were 4.51 (95% CI, 2.05–9.92; P
<.001) and 2.77 (95% CI, 1.18–6.47; P ¼ .02) for 26 and
52 weeks, respectively (Table 3). In a sensitivity analysis
in a dataset without imputed AST and ALT values we
found similar significant results (P < .001 for normali-
zation of transaminases at both 26 and 52 weeks).
To exclude the presence of cirrhosis as a confounder,
we performed a sensitivity analysis in patients without
cirrhosis at time of diagnosis in the discovery cohort,which demonstrated consistency with our primary
analysis. Rapid responders without cirrhosis had a
higher chance of normalization of transaminases at 26
and 52 weeks of treatment when compared with those
without cirrhosis who responded slower (OR, 3.62; 95%
CI, 1.81–7.26; P < .001 and OR, 4.18; 95% CI, 1.87–9.36;
P ¼ .001 for Week 26 and 52, respectively).
During a median follow-up of 6.2 years, liver-related
death or liver transplantation, as a composite endpoint,
occurred less frequently in rapid responders: 3.1%
versus 15.9% (log-rank P < .001) (Figure 1). This also
held for all-cause mortality, which occurred in 4.9% of
rapid responders versus 13.9% in slow responders (log-
rank P ¼ .001). Multivariable Cox regression showed that
rapid responders were at a lower risk of liver-related
death or transplantation (adjusted HR, 0.18; 95% CI,
0.05–0.63; P ¼ .007) and for all-cause mortality
(adjusted HR, 0.26; 95% CI, 0.09–0.75; P ¼ .01). Devel-
opment of hepatocellular carcinoma occurred only in the
slow responder group (2.8% vs 0%; P ¼ .01).
Slow responders in the discovery cohort who did not
achieve normalization of transaminases after 52 weeks of
treatment had higher rates of liver-related death or liver
transplantation when compared with slow responders
that did achieve normalization of transaminases after
Table 2.Outcomes in the Discovery Cohort: Patients With a
Rapid Treatment Response (>80% AST Decrease
After 8 Weeks of Treatment) Versus Patients Without












26 wk, n (%)
83 (57.2) 174 (77.3) < .001
Biochemical remission at
26 wk, n (%)a
46 (52.9) 108 (77.1) < .001
Predniso(lo)ne dose 10 mg
at 26 wk, n (%)
32 (22.1) 77 (34.2) .01
Normal transaminases at
52 wk, n (%)
94 (64.8) 195 (86.7) < .001
Biochemical remission at
52 wk, n (%)b
41 (61.2) 114 (79.7) .004
Predniso(lo)ne dose 10 mg
at 52 wk, n (%)
65 (44.8) 125 (55.6) .04
Liver-relateddeathorLTx,n (%) 23 (15.9) 7 (3.1) < .001
All-cause mortality, n (%) 20 (13.9) 11 (4.9) .002
HCC development, n (%) 4 (2.8) 0 .01
NOTE. Primary outcome was normalization of transaminases after 26 and 52
weeks of treatment. For patients with available IgG, we performed a subgroup
analysis for biochemical remission.
AST, aspartate aminotransferase; HCC, hepatocellular carcinoma; LTx, liver
transplantation.
aData available for 227 patients.
bData available for 210 patients.
June 2020 Rapid Treatment Response in AIH 161352 weeks: 35.3% versus 5.3% (P < .001). This difference
remained significant after multivariable Cox regression
(adjusted HR, 0.13; 95% CI, 0.03–0.52; P ¼ .004). Slow
responders who did not have normal transaminases after
52 weeks had higher pretreatment transaminases and
bilirubin and were more frequently cirrhotic
(Supplementary Table 2). Similar observations were
made in the validation cohort: slow responders that did
not reach normal transaminases after 52 weeks had
numerically higher rates of liver-related death or liver
transplantation, although this did not reach statisticalTable 3. Results of the Discovery Cohort After Multivariable Lo
80% AST Decrease After 8 Weeks of Treatment
Logistic regression Uncorrected OR
Normal transaminases at 26 wk 2.55 (1.62–4.01)
Biochemical remission at 26 wk 3.01 (1.69–5.36)
Normal transaminases at 52 wk 3.53 (2.11–5.90)
Biochemical remission at 52 wk 2.49 (1.32–4.72)
Cox regression Uncorrected HR
Liver-related death or LTx 0.18 (0.08–0.43)
All-cause mortality 0.32 (0.15–0.67)
NOTE. In all multivariable analyses we adjusted for institute, cirrhosis, AS-AIH, pre
baseline.
AS-AIH, acute-severe AIH; AST, aspartate aminotransferase; HR, hazard ratio; Osignificance: 16.0% versus 8.4% (P ¼ .17). However,
when corrected for confounders in the multivariate Cox
regression, reaching normal transaminases at Week 52
predicted a lower chance of liver-related death or
transplantation (adjusted HR, 0.27; 95% CI, 0.08–0.84;
P ¼ .02).Validation Cohort: Baseline Characteristics
In the validation cohort, 60.8% (225/370) of patients
were assigned to the rapid responder group. We
observed similar differences in baseline characteristics
as in the discovery cohort: rapid responders had higher
ALT, AST, bilirubin, and IgG at baseline (Supplementary
Table 3). Cirrhosis was unevenly but not significantly
distributed among rapid and slow responders (14.7% vs
20.7%; P ¼ .13). AS-AIH occurred in rapid responders
(13.7%) and slow responders (8.3%; P ¼ .11). Rapid
responders were treated with significantly higher pre-
dniso(lo)ne dosages when compared with slow re-
sponders (0.71 mg/kg/day vs 0.51 mg/kg/day; P <
.001), whereas use of maintenance therapy at Week 26
did not differ (73.3% vs 69.0%; P ¼ .36).Validation Cohort: Outcomes
Consistent with the results in the discovery cohort,
we found that rapid responders were more likely to
achieve normalization of transaminases after 26 and 52
weeks of treatment (73.3% vs 51.7%; P < .001 and
83.6% vs 65.5%; P < .001). The observation was made in
patients with available IgG for biochemical remission
after 26 and 52 weeks (72.8% vs 42.0%; P < .001 and
84.4% vs 56.8%; P < .001) (Table 4).
Multivariable logistic regression showed a significant
advantage for rapid responders for normalization of
transaminases after 26 and 52 weeks (OR, 2.97; 95% CI,
1.66–5.33; P < .001 and OR, 2.45; 95% CI, 1.28–4.69; P ¼
.007), or for biochemical remission at the same timegistic Regression and Cox Regression for Patients With a
P value Corrected OR P value
< .001 3.63 (1.94–6.79) < .001
< .001 4.51 (2.05–9.92) < .001
< .001 4.99 (2.44–10.24) < .001
.005 2.77 (1.18–6.47) .02
P value Corrected HR P value
< .001 0.18 (0.05–0.63) .007
.002 0.26 (0.09–0.75) .01
dniso(lo)ne dose, use of maintenance therapy, AST at baseline, and bilirubin at
R, odds ratio; LTx, liver transplantation.
Figure 1. Kaplan-Meier
curve of liver-related death
or transplantation over
time in the discovery
cohort. Patients with an
AST decrease of 80%
are compared with pa-
tients with an AST
decrease <80% (log-rank
P < .001). LTx, liver
transplantation.
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4.34; 95% CI, 1.77–10.65; P ¼ .001) (Table 5).
During a median follow-up of 6.2 years, liver-related
death or liver transplantation occurred more frequently
in slow responders: 11.0% versus 3.6% (log-rank p ¼
.006) (Supplementary Figure 1). A multivariable Cox
regression failed to assign statistical significance
(adjusted HR, 0.47; 95% CI, 0.16–1.39; P ¼ .17). Similar
results were seen for all-cause mortality (9.0% vs 4.9%;Table 4.Outcomes in the Validation Cohort: Patients With a
Rapid Treatment Response (>80% AST Decrease
After 8 Weeks of Treatment) Versus Patients Without












26 wk, n (%)
75 (51.7) 165 (73.3) < .001
Biochemical remission at
26 wk, n (%)a
34 (42.0) 99 (72.8) < .001
Predniso(lo)ne dose 10
mg at 26 wk, n (%)
33 (22.8) 71 (31.6) .07
Normal transaminases at
52 wk, n (%)
95 (65.5) 188 (83.6) < .001
Biochemical remission at
52 wk, n (%)b
50 (56.8) 114 (84.4) < .001
Predniso(lo)ne dose 10
mg at 52 wk, n (%)
67 (46.2) 135 (60.0) .009
Liver-related death or LTx,
n (%)
16 (11.0) 8 (3.6) .004
All-cause mortality, n (%) 13 (9.0) 11 (4.9) .12
HCC development, n (%) 0 0 —
NOTE. Primary outcome was normalization of transaminases after 26 and 52
weeks of treatment. For patients with available IgG, we performed a subgroup
analysis for biochemical remission.
AST, aspartate aminotransferase; HCC, hepatocellular carcinoma; LTx, liver
transplantation.
aData available for 217 patients.
bData available for 229 patients.log rank p ¼ .14; adjusted HR, 0.68; 95% CI, 0.26–1.79;
P ¼ .15).
Sensitivity Analysis With Alanine
Aminotransferase
We performed a sensitivity analysis in patients with
available ALT at Week 8 in the discovery cohort (n ¼
326) and the validation cohort (n ¼ 337). In both cohorts
we found that rapid responders based on ALT had a
higher likelihood for normalization of transaminases and
biochemical remission when compared with slow re-
sponders. The composite endpoint of liver trans-
plantation and liver-related death was significant in the
discovery cohort, but not in the validation cohort after
Cox regression (Supplementary Tables 4 and 5).
Subgroup Analysis in Patients With Cirrhosis
We performed a subgroup analysis in patients from
both cohorts combined who had cirrhosis at presentation
(Supplementary Table 6). Sixty-four (49.6%) were rapid
responders. In rapid responding patients with cirrhosis,
rates of normalization of transaminases were higher than
in those with a slow response: 73.4% versus 44.6% (P ¼
.001) and 79.7% versus 47.7% (P < .001) for 26 weeks
and 52 weeks, respectively, which remained significant
in the multivariable analysis (OR, 8.93; 95% CI,
2.69–29.69; P < .001; OR, 5.95; 95% CI, 1.92–18.50; P ¼
.002). Rates of biochemical remission were also higher in
the univariate analysis in rapid responding patients with
cirrhosis: 70% versus 40% (P ¼ .009) and 77.5% versus
48.5% (P ¼ .01) for 26 weeks and 52 weeks, respec-
tively. Only the 26-week time point remained significant
in the multivariable analysis (P ¼ .04 and P ¼ .42 for
Week 26 and 52, respectively). The composite endpoint
of liver-related death or transplantation occurred less
often in rapid responding patients with cirrhosis: 6.3%
versus 27.7% (P ¼ .001), although there was no signifi-
cant difference in the multivariable analysis (P ¼ .13).
Table 5. Results of the Validation Cohort After Multivariable Logistic Regression and Cox Regression for Patients With a 80%
AST Decrease After 8 Weeks of Treatment
Logistic regression Uncorrected OR P value Corrected OR P value
Normal transaminases at 26 wk 2.57 (1.65–3.98) < .001 2.97 (1.66–5.33) < .001
Biochemical remission at 26 wk 3.70 (2.07–6.61) < .001 3.62 (1.68–7.82) .001
Normal transaminases at 52 wk 2.67 (1.64–4.37) < .001 2.45 (1.28–4.69) .007
Biochemical remission at 52 wk 4.11 (2.21–7.64) < .001 4.34 (1.77–10.65) .001
Cox regression Uncorrected HR P value Corrected HR P value
Liver-related death or LTx 0.33 (0.14–0.77) .01 0.47 (0.16–1.39) .17
All-cause mortality 0.55 (0.25–1.14) .15 0.68 (0.26–1.79) .43
Note. In all multivariable analyses we adjusted for institute, cirrhosis, AS-AIH, predniso(lo)ne dose, use of maintenance therapy, AST at baseline, and bilirubin at
baseline.
AS-AIH, acute-severe AIH; AST, aspartate aminotransferase; HR, hazard ratio; OR, odds ratio; LTx, liver transplantation.
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We show that patients with AIH with a substantial
decrease (80%) of transaminases in the first 8 weeks of
treatment have a high chance of normalization of trans-
aminases and biochemical remission after 26 and 52weeks
of treatment. A rapid treatment response was indepen-
dently associated with a lower risk of liver-related death or
liver transplantation, although only in the discovery cohort.
The clinical consequence of these observations is that
80% decrease in transaminase levels within 8 weeks of
treatment initiation may serve as a predictor of long-term
disease course and serves as a clinical tool for patient
stratification. Additionally, we found that patients with AIH
with a slow treatment response who failed to reach
normalization of transaminases after 1 year of treatment
were at the highest risk for development of liver-related
mortality or transplantation.
High transaminases were associated with a rapid
response and it is possible these patients with acute AIH
are more susceptible to immunosuppressive treatment.
Lower baseline transaminases in the slow responders
might suggest a subclinical or protracted disease course
in the months/years preceding diagnosis, leading to a
delay in initiation of effective therapy, and poorer
response rates.11 Theoretically, a rapid and intense
suppression of the inflammatory response may lead to
hepatic stellate cell deactivation, cease proliferation of
myelofibroblasts, and prevent fibrosis development.12
Earlier studies on predictors of treatment response
showed that a diagnosis <18 years old, histologic
cirrhosis, and positive soluble liver antigen/liver
pancreas antigen were associated with poor short- and
long-term outcome.13 However, the concept of rapidity of
treatment response and its consequences has been
largely unexplored. Results of our study accord with
those of The King’s College group who described an as-
sociation between baseline AST levels and cirrhosis
development and long-term outcome.5 Patients with AST
levels at diagnosis less than 10 times ULN had a higher
risk on liver transplantation or death. Similarly, patientshad higher bilirubin levels and less cirrhosis at time of
diagnosis. Our study provides new and important clinical
information because we show that transaminase dy-
namics surpass a single AST measurement as a predictor
for outcomes in AIH. To further illustrate this, we strat-
ified patients from both cohorts combined according to
their initial AST elevation, which shows that a rapid
response has predictive value, regardless of baseline AST
level (Supplementary Table 7). Our data accord with
another, much smaller study that demonstrated that a
rapid treatment response (defined as a response within 6
months after treatment initiation) mitigated the risk for
the development of cirrhosis and need for liver
transplantation.14
We found that there is a wide phenotypical hetero-
geneity of AIH, in terms of variation of transaminases at
presentation. Both slow responders and AIH cirrhotics
have lower transaminases on presentation.15,16 However,
our sensitivity analysis in patients without cirrhosis gave
similar results, excluding cirrhosis as a confounding
factor. Moreover, a rapid treatment response after 8
weeks of treatment is associated with improved out-
comes regardless of presence of cirrhosis. These findings
indicate that even in in patients with cirrhosis, rapidity of
treatment response acts as a prognostic factor, although
the statistical power precludes us to confirm the benefit
for our composite outcome of liver-related death or
transplantation.
Our study comes with limitations. First, because of its
retrospective design, it carries selection bias. Only pa-
tients who had available serum transaminases in the first
weeks of treatment were included in this study. How-
ever, the large number of participating centers allows us
to collect a large AIH cohort that reflects real-world
practice. Second, rapid responders were treated with
higher predniso(lo)ne dosages, suggesting that steroid
dose might act as a confounder. Indeed, we noticed that
in a subgroup of patients with available data, cumulative
steroid dosages in the first year of treatment were
slightly lower in slow responders, although this was not
statistically significant. However, we have shown
1616 Pape et al Clinical Gastroenterology and Hepatology Vol. 18, No. 7previously that initial steroid dose is independent from
the likelihood of biochemical remission.17,18 We adjusted
for steroid dose in the logistic regression model, which
gave similar results to the univariate analysis. Third, we
used normalization of transaminases as our primary
endpoint, which contrasts international guidelines that
state that complete biochemical remission, including
normalization of IgG, should be the desired endpoint in
AIH.3,19 We found that IgG levels were not as frequently
measured as guidelines stipulate. This suggests decision
making in routine care is based on transaminases alone.
Therefore, we chose to incorporate biochemical remis-
sion as a secondary endpoint for patients with an avail-
able IgG at the time points of interest, which yield similar
results as our primary analysis.
Fourth, we do not provide data on histologic disease
activity at diagnosis or follow-up. Very few centers use
the hepatitis activity index in their histology reports.
Practical and logistic hurdles hampered us from
revising all the biopsy samples from the patients in our
cohort. Although older studies questioned the relation-
ship between normalization of serum markers and
complete histologic remission,20,21 a recent study
confirmed that biochemical remission is associated with
histologic disease activity and regression of fibrosis.4
Fifth, the concept of rapid treatment response
described in this study is only applicable to patients
that reach the 8-week time point. Our model is of little
value for patients with AIH who present with acute
liver failure that warrants immediate escalation of
therapy or transplantation because they were excluded
from our study. Sixth, we included patients with AS-AIH
in both our cohorts and included them in our primary
analysis. Although a subgroup analysis without AS-AIH
showed similar results (data not shown), one could
consider to exclude patients with AS-AIH in future
studies, given the differences in presentation, kinetics,
and prognosis. Lastly, missing data points hampered us
from investigating other predictive models that had a
slightly better performance than a model with AST
only. Additionally, we were unable to analyze various
factors that might have played a role in treatment
outcomes, such as compliance to therapy, flares of AIH,
and drug levels. Future studies should prospectively
validate models that include a combination of ALT, AST,
and bilirubin after 8 weeks of treatment.
The results of our study underline that a rapid and
substantial amelioration of biochemical inflammatory
activity is an important prognostic factor for remission of
AIH. The absence of such a response after 8 weeks might
be used to identify patients that might benefit from
intensified monitoring and escalation of treatment,
although this hypothesis needs future prospective
research. Because we observed that a large proportion of
patients without a rapid response ultimately achieved
biochemical remission, clinicians should be encouraged
to continue adequate immunosuppression with the goal
of later remission. In clinical practice, patients with AIHshould be monitored intensively during the first weeks
after initiation of treatment, to obtain a clear picture of
dynamics of transaminases.
To conclude, patients with AIH with a rapid treatment
response after 8 weeks of treatment have a favorable
disease course with a high likelihood of biochemical
remission and possibly a reduced risk for liver-related
mortality and liver transplantation. Moreover, these re-
sults suggest that stratification according to early treat-
ment response may also identify patients at greatest risk
and need for treatment intensification.Supplementary Material
Note: To access the supplementary material accom-
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curve of liver-related death
or transplantation over
time in the validation
cohort. Patients with an
AST decrease of 80% are
compared with patients
with an AST decrease
<80% (log-rank P ¼ .006).
LTx, liver transplantation.
Supplementary Table 1. Baseline and Treatment Characteristics of the Discovery and Validation Cohort
Discovery cohort (n ¼ 370) Validation cohort (n ¼ 370) P value
Female sex, n (%) 276 (74.6) 275 (74.3) .93
Age at diagnosis, y (SD) 47.09 (16.19) 49.58 (16.49) .04
Probable AIH diagnosis, n (%) 166 (44.9) 151 (40.8) .27
Definite AIH diagnosis, n (%) 204 (55.1) 219 (59.2) .27
ALT  ULN, median (IQR) 11.3 (23.04) 9.81 (21.84) .88
AST  ULN, median (IQR) 10.13 (19.52) 10.45 (22.19) .80
Bilirubin (mmol/L), median (IQR) 40 (145.2) 42.5 (152.3) .41
INR, median (IQR)a 1.10 (0.30) 1.20 (0.34) < .001
IgG (g/L), median (IQR) 21.1 (11.2) 18.4 (12.2) .06
Cirrhosis, n (%) 66 (17.8) 63 (17.0) .77
AS-AIH, n (%) 59 (15.9) 43 (11.6) .09
Treatment characteristics
Prednisone dose at start (mg/kg), median (IQR) 0.62 (0.59) 0.63 (0.57) .83
Predniso(lo)ne dose at start (mg/d), median (IQR) 40 (45) 40 (46) .87
On predniso(lo)ne at 26 wk, n (%) 245 (95.0) 243 (94.2) .70
Predniso(lo)ne dose at 26 wk (mg/d), median (IQR) 7.5 (5.0) 7.5 (5.0) .42
On predniso(lo)ne at 52 wk, n (%) 175 (82.5) 184 (82.1) .91
Predniso(lo)ne dose at 52 wk (mg/d), median (IQR) 5.0 (5.0) 5.0 (5.0) .81
Use of maintenance therapy at wk 26, n (%) 278 (75.1) 265 (71.6) .28
AZA 234 (63.2) 224 (60.5) .45
MMF 10 (2.7) 7 (1.9) .46
TAC 3 (0.8) 7 (1.9) .20
6-MP 15 (4.1) 11 (3.0) .43
6-TG 1 (0.3) 3 (0.8) .32
CsA 7 (1.9) 8 (2.2) .79
Other 8 (2.2) 5 (1.4) .40
6-MP, 6-mercaptopurine; 6-TG, 6-tioguanine; ALT, alanine aminotransferase; AS-AIH, acute-severe autoimmune hepatitis; AST, aspartate aminotransferase; AZA,
azathioprine, CsA, cyclosporine; IAIHG, International Autoimmune Hepatitis Group; INR, international normalized ratio; IQR, interquartile range; MMF, myco-
phenolate mofetil; SD, standard deviation; TAC, tacrolimus; ULN, upper limit of normal.
aAvailable for 288 patients.
1617.e1 Pape et al Clinical Gastroenterology and Hepatology Vol. 18, No. 7
Supplementary Table 2. Baseline Comparison of Slow Responders in the Discovery Cohort
Slow responders (n ¼ 145) in discovery cohort
Abnormal transaminases at
week 52 (n ¼ 51)
Normal transaminases at
week 52 (n ¼ 94) P value
Female sex, n (%) 34 (66.7) 71 (75.5) .25
Age at diagnosis, y (SD) 50.31 (16.06) 46.86 (16.53) .23
Probable AIH diagnosis, n (%) 22 (43.1) 44 (46.8) .67
Definite AIH diagnosis, n (%) 29 (56.9) 50 (53.2) .67
ALT  ULN, median (IQR) 4.25 (10.34) 2.67 (3.93) < .001
AST  ULN, median (IQR) 3.78 (4.81) 2.10 (3.43) < .001
Bilirubin (mmol/L), median (IQR) 36.0 (44.0) 14.68 (25.9) < .001
INR, median (IQR) 1.2 (0.36) 1.1 (0.19) < .001
IgG (g/L), median (IQR) 23.2 (13.4) 17.1 (8.8) .01
Cirrhosis, n (%) 20 (39.2) 15 (16.0) .002
AS-AIH, n (%) 6 (11.8) 4 (4.3) .09
NOTE. Slow responders in the discovery cohort who did not achieve normalization of transaminases at Week 52 had higher baseline ALT, AST, and bilirubin and
were more frequently cirrhotic.
ALT, alanine aminotransferase; AS-AIH, acute-severe autoimmune hepatitis; AST, aspartate aminotransferase; INR, international normalized ratio; IQR, inter-
quartile range; SD, standard deviation; ULN, upper limit of normal.
Supplementary Table 3. Baseline and Treatment Characteristics of the Validation Cohort
<80% AST decrease at
week 8 (n ¼ 145)
80% AST decrease at
week 8 (n ¼ 225) P value
Female sex, n (%) 104 (71.7) 171 (76.0) .36
Age at diagnosis, y (SD) 50.08 (15.74) 49.26 (16.92) .64
Probable AIH diagnosis, n (%) 52 (35.9) 99 (44.0) .12
Definite AIH diagnosis, n (%) 93 (64.1) 126 (56.0) .12
ALT  ULN, median (IQR) 3.5 (4.83) 22.89 (26.48) < .001
AST  ULN, median (IQR) 2.87 (4.38) 22.39 (23.24) < .001
Bilirubin (mmol/L), median (IQR) 17 (26.5) 85.5 (171.1) < .001
INR, median (IQR)a 1.18 (0.45) 1.18 (0.35) .82
IgG (g/L), median (IQR) 19.6 (9.5) 21.8 (12.0) .02
Cirrhosis, n (%) 30 (20.7) 33 (14.7) .13
AS-AIH, n (%) 12 (8.3) 31 (13.8) .11
Treatment characteristics
Prednisone dose at start (mg/kg), median (IQR) 0.53 (0.51) 0.71 (0.72) < .001
Predniso(lo)ne dose at start (mg/d), median (IQR) 40 (35) 40 (60) < .001
On predniso(lo)ne at 26 wk, n (%) 97 (96.0) 146 (93.0) .31
Predniso(lo)ne dose at 26 wk (mg/d), median (IQR) 7.5 (5.0) 7.5 (5.0) .08
On predniso(lo)ne at 52 wk, n (%) 67 (84.8) 117 (80.7) .44
Predniso(lo)ne dose at 52 wk (mg/day), median (IQR) 5.0 (7.0) 5.0 (5.0) .02
Use of maintenance therapy at wk 26, n (%) 100 (69.0) 165 (73.3) .36
AZA 82 (56.6) 143 (63.1) .21
MMF 3 (2.1) 4 (1.8) .84
TAC 4 (2.8) 3 (1.3) .33
6-MP 2 (1.4) 9 (4.0) .15
6-TG 1 (0.7) 2 (0.9) .84
CsA 5 (3.4) 3 (1.3) .17
Other 2 (1.4) 0 .08
NOTE. Patients are divided into 2 groups based on their treatment response.
6-MP, 6-mercaptopurine; 6-TG, 6-tioguanine; ALT, alanine aminotransferase; AS-AIH, acute-severe autoimmune hepatitis; AST, aspartate aminotransferase; AZA,
azathioprine; CsA, cyclosporine; IAIHG, International Autoimmune Hepatitis Group; INR, international normalized ratio; IQR, interquartile range; MMF, myco-
phenolate mofetil; SD, standard deviation; TAC, tacrolimus; ULN, upper limit of normal.
aAvailable for 579 patients.
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Supplementary Table 4.Outcomes in the Discovery Cohort: Sensitivity Analysis in Patients With a Rapid Treatment Response
Based on ALT Instead of AST (>80% ALT Decrease After 8 Weeks of Treatment
<80% ALT decrease at week
8 (n ¼ 145)
80% ALT decrease
at week 8 (n ¼ 182) P value
Normal transaminases at 26 wk, n (%) 79 (54.5) 142 (78.0) < .001
Biochemical remission at 26 wk, n (%)a 45 (53.6) 87 (77.0) .001
Normal transaminases at 52 wk, n (%) 93 (64.1) 157 (86.3) < .001
Biochemical remission at 52 wk, n (%)b 42 (60.0) 93 (83.8) < .001
Liver-related death or LTx, n (%) 21 (14.5) 7 (3.8) .001
All-cause mortality, n (%) 19 (13.2) 10 (5.5) .02
Logistic regression Uncorrected OR P value Corrected OR P value
Normal transaminases 26 wk 2.97 (1.84–4.79) < .001 5.53 (2.83–1 .80) < .001
Biochemical remission 26 wk 2.90 (1.57–5.35) .001 4.76 (2.11–1 .70) < .001
Normal transaminases 52 wk 3.51 (2.04–6.04) < .001 6.58 (3.08–14.06) < .001
Biochemical remission 52 wk 3.44 (1.72–6.90) < .001 5.15 (2.05–12.95) < .001
Cox regression Uncorrected HR P value Corrected HR P value
Liver-related death or LTx 0.21 (0.09–0.51) .001 .28 ( .09– .93) .04
All-cause mortality 0.36 (0.17–0.77) .009 .51 ( .18–1.44) .20
ALT, alanine aminotransferase; HR, hazard ratio; LTx, liver transplantation; OR, odds ratio.
aData available for 197 patients.
bData available for 181 patients.
Supplementary Table 5. Outcomes in the Validation Cohort: Sensitivity Analysis in Patients With a Rapid Treatment Response
Based on ALT Instead of AST (>80% ALT Decrease After 8 Weeks of Treatment
<80% ALT decrease at
week 8 (n ¼ 143)
80% ALT decrease
at week 8 (n ¼ 194) P value
Normal transaminases at 26 wk, n (%) 73 (51.0) 140 (72.2) < .001
Biochemical remission at 26 wk, n (%)a 35 (44.3) 80 (72.1) < .001
Normal transaminases at 52 wk, n (%) 94 (65.7) 157 (80.9) .002
Biochemical remission at 52 wk, n (%)b 50 (57.5) 94 (83.2) < .001
Liver-related death or LTx, n (%) 15 (10.5) 9 (4.6) .04
All-cause mortality, n (%) 13 (9.1) 10 (5.2) .16
Logistic regression Uncorrected OR P value Corrected OR P value
Normal transaminases 26 wk 2.49 (1.58–3.91) < .001 2.88 (1.57–5.28) .001
Biochemical remission 26 wk 3.24 (1.77–5.96) < .001 3.76 (1.65–8.59) .002
Normal transaminases 52 wk 2.21 (1.35–3.64) .002 2.00 (1.04–3.86) .04
Biochemical remission 52 wk 3.36 (1.90–7.02) < .001 3.42 (1.36–8.56) .01
Cox regression Uncorrected HR P value Corrected HR P value
Liver-related death or LTx 0.47 (0.21–1.08) .08 .83 ( .29–2.42) .74
All-cause mortality 0.65 (0.28–1.49) .31 .91 ( .32–2.57) .85
ALT, alanine aminotransferase; HR, hazard ratio; LTx, liver transplantation; OR, odds ratio.
aData available for 190 patients.
bData available for 200 patients.
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Supplementary Table 6. Baseline Characteristics and Outcomes of Patients With Cirrhosis at Presentation
Baseline
<80% AST decrease at
week 8 (n ¼ 65)
80% AST decrease at
week 8 (n ¼ 64) P value
Female sex, n (%) 47 (72.3) 44 (68.8) .66
Age at diagnosis, y (SD) 49.45 (16.85) 51.64 (16.07) .45
Prednisone dose at start (mg/kg), median (IQR) 0.51 (0.48) 0.62 (2.01) .02
ALT  ULN, median (IQR) 3.09 (5.30) 16.20 (21.12) < .001
AST  ULN, median (IQR) 3.03 (4.12) 17.71 (20.66) < .001
Bilirubin (mmol/L), median (IQR) 27.0 (38.6) 83 (234) < .001
IgG (g/L), median (IQR) 19.1 (16.1) 20.7 (15.6) .35
Outcomes, n (%)
Normal transaminases at 26 wk 29 (44.6) 47 (73.4) .001
Biochemical remission at 26 wka 14 (40) 28 (70.0) .009
Predniso(lo)ne dose 10 mg at 26 wk 16 (24.6) 23 (35.9) .16
Normal transaminases at 52 wk 31 (47.7) 51 (79.7) < .001
Biochemical remission at 52 wkb 16 (48.5) 31 (77.5) .01
Predniso(lo)ne dose 10 mg at 52 wk 26 (40) 35 (54.7) .10
Liver-related death or LTx 18 (27.7) 4 (6.3) .001
All-cause mortality 15 (23.1) 7 (10.6) .07
HCC development 2 (3.1) 0 .16
ALT, alanine aminotransferase; AS-AIH, acute-severe autoimmune hepatitis; AST, aspartate aminotransferase; HCC, hepatocellular carcinoma; IQR, interquartile
range; LTx, liver transplantation.
aData available for 75 patients.
bData available for 73 patients.
Supplementary Table 7. Rates of Normalization of Transaminases in Both Cohorts Combined
<80% AST decrease at week 8 >80% AST decrease at week 8 P value
AST at baseline 0.28–4.81  ULN
Normal transaminases at week 26, n (%) 136 (66.3) 35 (87.5) .008
AST baseline 4.82–19.31  ULN
Normal transaminases at week 26, n (%) 16 (22.2) 128 (74.4) < .001
AST baseline 19.32–140  ULN
Normal transaminases at week 26, n (%) 3 (30.0) 173 (74.2) .002
NOTE. Patients are stratified according to their AST elevation at baseline. Patients with low AST at baseline but a rapid AST response demonstrate higher rates of
normalization of transaminases compared with patients without such a response, even compared when patients have initial high AST. AST, aspartate amino-
transferase; ULN, upper limit of normal.
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